RBC Capital Maintains Outperform on 89bio, Raises Price Target to $34
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams maintains an 'Outperform' rating on 89bio (NASDAQ:ETNB) and raises the price target from $33 to $34.
August 10, 2023 | 2:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital maintains an 'Outperform' rating on 89bio and raises the price target from $33 to $34, indicating a positive outlook for the company.
The raised price target by RBC Capital indicates a positive outlook for 89bio. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100